2024 annual financial data
Scinai Immunotherapeutics 2024 Net income growth
Direct answer
Net income growth was 173.78%.
Operating income was -8,638,000 USD and net income was 4,796,000 USD.
Operating cash flow was -6,335,000 USD.
Get free Scinai Immunotherapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 658,000 USD
- Operating income
- -8,638,000 USD
- Net income
- 4,796,000 USD
- Operating cash flow
- -6,335,000 USD